BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 29407963)

  • 21. Heterocyclization of 2-(2-phenylhydrazono)cyclohexane-1,3-dione to Synthesis Thiophene, Pyrazole and 1,2,4-triazine Derivatives with Anti-Tumor and Tyrosine Kinase Inhibitions.
    Mohareb RM; Alwan ES
    Anticancer Agents Med Chem; 2020; 20(10):1209-1220. PubMed ID: 32156245
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In-vitro Anti-cancer assay and apoptotic cell pathway of newly synthesized benzoxazole-N-heterocyclic hybrids as potent tyrosine kinase inhibitors.
    Desai S; Desai V; Shingade S
    Bioorg Chem; 2020 Jan; 94():103382. PubMed ID: 31662214
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design, Synthesis, and Biological Evaluation of 4-Phenoxyquinoline Derivatives Containing Benzo[d]thiazole-2-yl Urea as c-Met Kinase Inhibitors.
    Lei H; Hu G; Wang Y; Han P; Liu Z; Zhao Y; Gong P
    Arch Pharm (Weinheim); 2016 Aug; 349(8):651-61. PubMed ID: 27283017
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of 1-(3-aryl-4-chlorophenyl)-3-(p-aryl)urea derivatives against breast cancer by inhibiting PI3K/Akt/mTOR and Hedgehog signalings.
    Li W; Sun Q; Song L; Gao C; Liu F; Chen Y; Jiang Y
    Eur J Med Chem; 2017 Dec; 141():721-733. PubMed ID: 29107429
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel Tetrahydrobenzo [b] Thiophene Compounds Exhibit Anticancer Activity through Enhancing Apoptosis and Inhibiting Tyrosine Kinase.
    El-Metwally SA; Khalil AK; El-Naggar AM; El-Sayed WM
    Anticancer Agents Med Chem; 2018; 18(12):1761-1769. PubMed ID: 30101717
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design, synthesis and biological evaluation of bis-aryl ureas and amides based on 2-amino-3-purinylpyridine scaffold as DFG-out B-Raf kinase inhibitors.
    Yang W; Chen Y; Zhou X; Gu Y; Qian W; Zhang F; Han W; Lu T; Tang W
    Eur J Med Chem; 2015 Jan; 89():581-96. PubMed ID: 25462267
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design, synthesis and biological evaluation of novel 4-phenoxy-6,7-disubstituted quinolines possessing (thio)semicarbazones as c-Met kinase inhibitors.
    Zhai X; Bao G; Wang L; Cheng M; Zhao M; Zhao S; Zhou H; Gong P
    Bioorg Med Chem; 2016 Mar; 24(6):1331-45. PubMed ID: 26897090
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery of novel diaryl urea derivatives bearing a triazole moiety as potential antitumor agents.
    Qin M; Yan S; Wang L; Zhang H; Zhao Y; Wu S; Wu D; Gong P
    Eur J Med Chem; 2016 Jun; 115():1-13. PubMed ID: 26991938
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New diarylamides and diarylureas possessing 8-amino(acetamido)quinoline scaffold: synthesis, antiproliferative activities against melanoma cell lines, kinase inhibition, and in silico studies.
    Koh EJ; El-Gamal MI; Oh CH; Lee SH; Sim T; Kim G; Choi HS; Hong JH; Lee SG; Yoo KH
    Eur J Med Chem; 2013; 70():10-21. PubMed ID: 24128410
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design and synthesis of new RAF kinase-inhibiting antiproliferative quinoline derivatives. Part 2: Diarylurea derivatives.
    El-Gamal MI; Khan MA; Tarazi H; Abdel-Maksoud MS; Gamal El-Din MM; Yoo KH; Oh CH
    Eur J Med Chem; 2017 Feb; 127():413-423. PubMed ID: 28088086
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacophore-based virtual screening, synthesis, biological evaluation, and molecular docking study of novel pyrrolizines bearing urea/thiourea moieties with potential cytotoxicity and CDK inhibitory activities.
    Shawky AM; Ibrahim NA; Abourehab MAS; Abdalla AN; Gouda AM
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):15-33. PubMed ID: 33103497
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery of 1-(1H-Pyrazolo[4,3-c]pyridin-6-yl)urea Inhibitors of Extracellular Signal-Regulated Kinase (ERK) for the Treatment of Cancers.
    Lim J; Kelley EH; Methot JL; Zhou H; Petrocchi A; Chen H; Hill SE; Hinton MC; Hruza A; Jung JO; Maclean JK; Mansueto M; Naumov GN; Philippar U; Raut S; Spacciapoli P; Sun D; Siliphaivanh P
    J Med Chem; 2016 Jul; 59(13):6501-11. PubMed ID: 27329786
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery of a broad spectrum antiproliferative agent with selectivity for DDR1 kinase: cell line-based assay, kinase panel, molecular docking, and toxicity studies.
    Elkamhawy A; Park JE; Cho NC; Sim T; Pae AN; Roh EJ
    J Enzyme Inhib Med Chem; 2016; 31(1):158-66. PubMed ID: 25807298
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of novel quinoline analogues bearing thiazolidinones as potent kinase inhibitors for the treatment of colorectal cancer.
    Zhou Y; Xu X; Wang F; He H; Gong G; Xiong L; Qi B
    Eur J Med Chem; 2020 Oct; 204():112643. PubMed ID: 32731184
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Soluble 2-substituted aminopyrido[2,3-d]pyrimidin-7-yl ureas. Structure-activity relationships against selected tyrosine kinases and exploration of in vitro and in vivo anticancer activity.
    Schroeder MC; Hamby JM; Connolly CJ; Grohar PJ; Winters RT; Barvian MR; Moore CW; Boushelle SL; Crean SM; Kraker AJ; Driscoll DL; Vincent PW; Elliott WL; Lu GH; Batley BL; Dahring TK; Major TC; Panek RL; Doherty AM; Showalter HD
    J Med Chem; 2001 Jun; 44(12):1915-26. PubMed ID: 11384237
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design, synthesis and evaluation of acridine derivatives as multi-target Src and MEK kinase inhibitors for anti-tumor treatment.
    Cui Z; Li X; Li L; Zhang B; Gao C; Chen Y; Tan C; Liu H; Xie W; Yang T; Jiang Y
    Bioorg Med Chem; 2016 Jan; 24(2):261-9. PubMed ID: 26707846
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design, synthesis, biological evaluation and molecular modeling of novel 2-amino-4-(1-phenylethoxy) pyridine derivatives as potential ROS1 inhibitors.
    Tian Y; Zhang T; Long L; Li Z; Wan S; Wang G; Yu Y; Hou J; Wu X; Zhang J
    Eur J Med Chem; 2018 Jan; 143():182-199. PubMed ID: 29174814
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthesis, Molecular Modeling and Biological Evaluation of 4-Alkoxyquinazoline Derivatives as Novel Inhibitors of VEGFR2.
    Lu L; Zhao TT; Liu TB; Sun WX; Xu C; Li DD; Zhu HL
    Chem Pharm Bull (Tokyo); 2016 Nov; 64(11):1570-1575. PubMed ID: 27568484
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rational modification of semaxanib and sunitinib for developing a tumor growth inhibitor targeting ATP binding site of tyrosine kinase.
    Kaur J; Kaur B; Singh P
    Bioorg Med Chem Lett; 2018 Jan; 28(2):129-133. PubMed ID: 29208523
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting tyrosine kinase: Development of acridone - pyrrole - oxindole hybrids against human breast cancer.
    Kaur M; Singh P
    Bioorg Med Chem Lett; 2019 Jan; 29(1):32-35. PubMed ID: 30446310
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.